ID

20232

Description

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

Mots-clés

Versions (2)
  1. 15/02/2017 15/02/2017 -
  2. 20/02/2017 20/02/2017 -
Téléchargé le

15 février 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Visit 1A Events PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

Anglais

Visit 1A Events PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

1 Formulaires  
Events
Description

Events

Alias
UMLS CUI-1
C0877248
1. Has the patient experienced any of the following since randomization:
Description

Patient experience

Type de données

text

Dizziness or Lightheadedness
Description

Dizziness or Lightheadedness

Type de données

boolean

Fainting
Description

Fainting

Type de données

boolean

Alias
UMLS CUI [1]
C0039070
Headache during first week of study drug administration
Description

Headache

Type de données

boolean

If headache occurred please indicate how it was treated (indicate all that apply):
Description

If headache

Type de données

integer

2. Have any Outcome Events or Serious Adverse Events been experienced? (See instructions on facing page)
Description

Outcome Events or Serious Adverse Events

Type de données

boolean

if "Yes" please indicate all that apply
Description

If Yes

Type de données

integer

Please complete the respective forms
Description

Please complete the respective forms

4. Signature of Investigator or Sub-Investigator
Description

By signing and dating this page, I declare that I have reviewed for accuracy all the case report form pages for this patient visit; the information contained on these pages accurately reflects the medical record including the results of tests and evaluations performed on the specified dates.

Type de données

text

Date of Signature (dd mon yy)
Description

Date of Signature

Type de données

date

Retour au début de la page

Similar models

Visit 1A Events PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Events
C0877248 (UMLS CUI-1)
Patient experience
Item
1. Has the patient experienced any of the following since randomization:
text
Dizziness or Lightheadedness
Item
Dizziness or Lightheadedness
boolean
Fainting
Item
Fainting
boolean
C0039070 (UMLS CUI [1])
Headache
Item
Headache during first week of study drug administration
boolean
Item
If headache occurred please indicate how it was treated (indicate all that apply):
integer
If headache
Code List
If headache occurred please indicate how it was treated (indicate all that apply):
CL Item
Analgestic (1)
CL Item
Down titration of study medication A (2)
CL Item
No treatment (3)
Outcome Events or Serious Adverse Events
Item
2. Have any Outcome Events or Serious Adverse Events been experienced? (See instructions on facing page)
boolean
Item
if "Yes" please indicate all that apply
integer
If Yes
Code List
if "Yes" please indicate all that apply
CL Item
Stroke (1)
CL Item
Myocardial Infarction (2)
CL Item
Death (3)
CL Item
New or worsening congestive heart failure (CHF) (4)
CL Item
Other designated vascular event (5)
CL Item
Hemorrhagic Event (6)
CL Item
Thrombotic Thrombocytopenia purpura (7)
CL Item
Neutropenia (8)
CL Item
Newly diagnosed diabetes (9)
Item Group
Please complete the respective forms
Signature of Investigator or Sub-Investigator
Item
4. Signature of Investigator or Sub-Investigator
text
Date of Signature
Item
Date of Signature (dd mon yy)
date
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial